In-Depth Insights into the Glomerulonephritis Market: Growth, Trends, and Opportunities for 2025-2034
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the glomerulonephritis market size evolved in recent years?
In recent times, the glomerulonephritis market has experienced substantial growth. The market size, which stood at $11.06 billion in 2024, is projected to climb to $11.64 billion in 2025, registering a compound annual growth rate (CAGR) of 5.3%. The growth of the market in the historic period is attributed to factors such as the increasing cases of kidney disorders, widespread infections like post-streptococcal glomerulonephritis, advancement in research and development, the surge in kidney failure incidents, and heightened awareness related to kidney diseases.
What are the predictions for the glomerulonephritis market size in the coming years?
Anticipating robust expansion in the upcoming years, the glomerulonephritis market size is predicted to reach $14.14 billion by 2029, with a compound annual growth rate (CAGR) of 5.0%. The forecast period’s escalation can be attributed to a rise in diabetes cases, a burgeoning elderly population, an escalation in healthcare expenditure, a surge in dialysis patients, and an uptick in autoimmune diseases. The emerging trends within the predicted period encompass the introduction of novel treatments and therapies, enhancements in diagnostic technologies, new therapeutics, partnerships among corporations, and the application of intravenous immunoglobulin therapy.
Get your glomerulonephritis market report here!
https://www.thebusinessresearchcompany.com/report/glomerulonephritis-global-market-report
What key factors are fueling the growth of the glomerulonephritis market?
The glomerulonephritis market is set to grow as a result of the increasing incidence of kidney disorders. Conditions which adversely affect the structure or functionality of kidneys, leading to compromised waste removal, filtration, and fluid balance, are referred to as kidney disorders. Factors paving the way to their increasing occurrence include aging demographics, escalated instances of chronic illnesses such as hypertension and diabetes, and lifestyle decisions. The role of kidney disorders in triggering glomerulonephritis includes chronic inflammation, immune system malfunction, or structural damage, which then leads to impaired kidney filtration. For instance, the Australian Institute of Health and Welfare, a government agency based in Australia, stated in December 2024 that chronic kidney disease (CKD) mortality rates had grown by 4.2% in 2021 and 6.2% in 2022. CKD was implicated in roughly 2 million hospital admissions in 2021-22, accounting for 18% of all Australia’s hospitalizations. Thus, the growing frequency of kidney disorders is likely to fuel the expansion of the glomerulonephritis market.
How is the global glomerulonephritis market divided into key segments?
The glomerulonephritis market covered in this report is segmented –
1) By Type: Acute Glomerulonephritis, Chronic Glomerulonephritis
2) By Diagnosis: Urine And Blood Tests, Imaging Tests, Kidney Biopsy, Other Diagnosis
3) By Treatment: Medication, Surgery, Dialysis, Other Treatments
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
5) By End-User: Hospitals, Specialty Clinics, Other End-Users
Subsegments:
1) By Acute Glomerulonephritis: Post-infectious Glomerulonephritis, IgA Nephropathy, Lupus Nephritis, Rapidly Progressive Glomerulonephritis (RPGN), Goodpasture Syndrome
2) By Chronic Glomerulonephritis: Focal Segmental Glomerulosclerosis (FSGS), Membranous Nephropathy, Minimal Change Disease, Alport Syndrome, Diabetic Nephropathy, Hypertensive Nephrosclerosis
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21193&type=smp
Who are the key firms paving the way for growth in the glomerulonephritis market?
Major companies operating in the glomerulonephritis market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Asahi Kasei Medical Co. Ltd., Boehringer Ingelheim International GmbH, DaVita Inc., Biogen Inc., Merit Medical Systems Inc., Apellis Pharmaceuticals Inc., MorphoSys AG, Travere Therapeutics Inc., Vera Therapeutics Inc., Calliditas Therapeutics AB, Omeros Corporation, Otsuka Pharmaceutical Co. Ltd., Aurinia Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., NovelMed Therapeutics Inc.
What key trends are currently impacting the glomerulonephritis market’s development?
In the glomerulonephritis market, leading companies are striving to innovate and develop advanced non-immunosuppressive treatments to cater to unresolved medical demands and enhance patient recovery. Non-immunosuppressive treatments are the ones that neither downtrend nor suppress the immunity of a person and aim to treat conditions without affecting immune functionality. For example, in September 2024, a significant advancement was made by Travere Therapeutics Inc., a bio-pharmaceutical firm based in the US. They introduced FILSPARI (sparsentan), which got the approval of the Food and Drug Administration (FDA) for the treatment of IgA nephropathy, a type of kidney disease. This drug, being the sole non-immunosuppressive treatment, has been proven to considerably decelerate the decline of kidney functionality in these patients. FILSPARI’s approval signifies a significant milestone in managing IgA nephropathy, which is the most recurrent type of primary glomerulonephritis. With this therapy, a novel alternative has been made available to patients previously having only limited options. This approval emphasizes Travere’s dedication to enhancing patient outcomes dealing with kidney disease.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21193
What regions are contributing significantly to the growth of the glomerulonephritis market?
North America was the largest region in the glomerulonephritis market in 2024. The regions covered in the glomerulonephritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Suture Laparoscopic Forceps Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/suture-laparoscopic-forceps-global-market-report
Electrocautery Enhanced Delivery System Global Market Report 2025
Anemia and Other Blood Disorder Drugs Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
